Johnson & Johnson (JNJ) director receives 975 deferred share units grant

Rhea-AI Filing Summary

Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.

Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider West Nadja

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	975	$0.00	--

Holdings After Transaction: Deferred Share Units — 7,730.049 shares (Direct, null)

Footnotes (1)

1. Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.

Key Figures

Deferred Share Units granted: 975 units Grant price per unit: $0.00 per unit Total DSUs after transaction: 7,730.0491 units +1 more

4 metrics

Deferred Share Units granted 975 units Grant to director Nadja West on April 23, 2026

Grant price per unit $0.00 per unit Deferred Share Units award under director deferred fee plan

Total DSUs after transaction 7,730.0491 units Director Nadja West holdings following the April 23, 2026 grant

Underlying common stock equivalence 1 share per DSU Each DSU equals fair market value of one JNJ share at settlement

Key Terms

Deferred Share Units, Amended and Restated Deferred Fee Plan for Directors, dividend equivalent rights

3 terms

Deferred Share Units financial

"Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors"

Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.

Amended and Restated Deferred Fee Plan for Directors financial

"acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors"

dividend equivalent rights financial

"Includes dividend equivalent rights in connection with the Issuer's quarterly dividend"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

West Nadja

(Last) (First) (Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK NEW JERSEY 08933

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	04/23/2026		A		975		(1)	(1)	Common Stock	975	$0	7,730.0491(2)	D

Explanation of Responses:

1. Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).

2. Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.

Remarks:

	/s/ Joleen Morgan, as attorney-in-fact for Nadja Y. West	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Johnson & Johnson (JNJ) director Nadja West report in this Form 4?

Director Nadja West reported receiving 975 Deferred Share Units (DSUs) of Johnson & Johnson on April 23, 2026. The award was granted at $0.00 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors.

How many Deferred Share Units does Nadja West hold after this JNJ transaction?

After this grant, Nadja West holds a total of 7,730.0491 Deferred Share Units. This total includes the newly awarded 975 DSUs, plus previously held units and related dividend equivalent rights that accrue with Johnson & Johnson’s quarterly dividends.

How and when will Nadja West’s Johnson & Johnson Deferred Share Units be settled?

The Deferred Share Units will be settled in cash upon the termination of Nadja West’s Johnson & Johnson directorship. Each DSU represents the fair market value of one share of Johnson & Johnson common stock on the settlement date, according to the plan terms.

Are Nadja West’s Deferred Share Units in JNJ tied to dividends?

Yes. The filing states the holdings include dividend equivalent rights connected to Johnson & Johnson’s quarterly dividend. These rights accrue on the DSUs held, increasing the number of units credited to Nadja West over time as dividends are paid.

Is Nadja West’s JNJ Form 4 transaction an open-market stock purchase or sale?

No. The Form 4 describes a grant or award acquisition of 975 Deferred Share Units at $0.00 per unit. It is compensation under Johnson & Johnson’s director deferred fee plan, not an open-market stock purchase or sale transaction.